Your browser doesn't support javascript.
loading
Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.
Masui, Sho; Yonezawa, Atsushi; Nakamura, Miyuki; Onishi, Akira; Hashimoto, Motomu; Onizawa, Hideo; Fujii, Takayuki; Murakami, Kosaku; Murata, Koichi; Tanaka, Masao; Yokoyama, Kotoko; Iwamoto, Noriko; Shimada, Takashi; Itohara, Kotaro; Hira, Daiki; Nakagawa, Shunsaku; Imai, Satoshi; Nakagawa, Takayuki; Hayakari, Makoto; Matsuda, Shuichi; Morinobu, Akio; Terada, Tomohiro; Matsubara, Kazuo.
Afiliação
  • Masui S; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
  • Yonezawa A; Graduate School of Pharmaceutical Sciences, Kyoto University.
  • Nakamura M; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
  • Onishi A; Graduate School of Pharmaceutical Sciences, Kyoto University.
  • Hashimoto M; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
  • Onizawa H; Graduate School of Pharmaceutical Sciences, Kyoto University.
  • Fujii T; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University.
  • Murakami K; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University.
  • Murata K; Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine.
  • Tanaka M; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University.
  • Yokoyama K; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University.
  • Iwamoto N; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University.
  • Shimada T; Center for Cancer Immunotherapy and Immunobiology, Division of Clinical Immunology and Cancer Immunotherapy, Graduate School of Medicine, Kyoto University.
  • Itohara K; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University.
  • Hira D; Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University.
  • Nakagawa S; Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University.
  • Imai S; SHIMADZU Corporation.
  • Nakagawa T; SHIMADZU Corporation.
  • Hayakari M; SHIMADZU Corporation.
  • Matsuda S; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
  • Morinobu A; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
  • Terada T; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
  • Matsubara K; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
Biol Pharm Bull ; 46(8): 1112-1119, 2023.
Article em En | MEDLINE | ID: mdl-37532562
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Interleucina-6 / Antirreumáticos / Infliximab Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Interleucina-6 / Antirreumáticos / Infliximab Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article